{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Evolocumab+Injections",
    "query": {
      "intervention": "Evolocumab Injections"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 47,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Evolocumab+Injections&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T22:10:12.758Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02585895",
      "title": "Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low-density Lipoprotein Cholesterol (LDL-C) Apheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2015-12-21",
      "completion_date": "2017-01-20",
      "has_results": true,
      "last_update_posted_date": "2022-11-30",
      "last_synced_at": "2026-09-12T22:10:12.758Z",
      "location_count": 4,
      "location_summary": "Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Grandville",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02585895"
    },
    {
      "nct_id": "NCT03900026",
      "title": "Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Bypass Graft Surgery",
        "Atherosclerosis",
        "Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Unity Health Toronto",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 782,
      "start_date": "2019-05-30",
      "completion_date": "2025-01-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-09-12T22:10:12.758Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Jacksonville, Florida • Portland, Maine + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Maine"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03900026"
    },
    {
      "nct_id": "NCT02833844",
      "title": "Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 467,
      "start_date": "2017-05-22",
      "completion_date": "2020-01-27",
      "has_results": true,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-09-12T22:10:12.758Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02833844"
    },
    {
      "nct_id": "NCT04937413",
      "title": "The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Malignant Glioma",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2021-10-08",
      "completion_date": "2023-10-12",
      "has_results": false,
      "last_update_posted_date": "2024-06-25",
      "last_synced_at": "2026-09-12T22:10:12.758Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04937413"
    },
    {
      "nct_id": "NCT01849497",
      "title": "Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Hypercholesterolemia",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab Pre-filled Syringe",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Evolocumab AI/pen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 149,
      "start_date": "2013-04-18",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-09-12T22:10:12.758Z",
      "location_count": 21,
      "location_summary": "Encino, California • Thousand Oaks, California • Ventura, California + 17 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Westlake Village",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01849497"
    },
    {
      "nct_id": "NCT01813422",
      "title": "GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 970,
      "start_date": "2013-04-18",
      "completion_date": "2016-07-29",
      "has_results": true,
      "last_update_posted_date": "2019-02-20",
      "last_synced_at": "2026-09-12T22:10:12.758Z",
      "location_count": 59,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01813422"
    },
    {
      "nct_id": "NCT01624142",
      "title": "Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Severe Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 300,
      "start_date": "2012-06-01",
      "completion_date": "2018-05-11",
      "has_results": true,
      "last_update_posted_date": "2024-05-28",
      "last_synced_at": "2026-09-12T22:10:12.758Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • New York, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624142"
    },
    {
      "nct_id": "NCT03570697",
      "title": "Imaging of Coronary Plaques in Participants Treated With Evolocumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Artery Disease (CAD)"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Statin therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2018-11-19",
      "completion_date": "2021-01-21",
      "has_results": true,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-09-12T22:10:12.758Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Elkhart, Indiana + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Elkhart",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03570697"
    },
    {
      "nct_id": "NCT01380730",
      "title": "LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 631,
      "start_date": "2011-07-01",
      "completion_date": "2012-04-05",
      "has_results": true,
      "last_update_posted_date": "2022-11-15",
      "last_synced_at": "2026-09-12T22:10:12.758Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Malvern, Arkansas + 48 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Malvern",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01380730"
    },
    {
      "nct_id": "NCT01854918",
      "title": "Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia and Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 3681,
      "start_date": "2013-04-23",
      "completion_date": "2018-05-31",
      "has_results": true,
      "last_update_posted_date": "2019-06-11",
      "last_synced_at": "2026-09-12T22:10:12.758Z",
      "location_count": 107,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01854918"
    }
  ]
}